Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.4
Serina Therapeutics, Inc.: Company agreed to amend bylaws to provide for co-chairmen of the Board, with each co-chairman having same rights and responsibilities, effective upon closing of initial tranche of private placement.
- Change
- bylaw amendment
Exact text from the filing
the Company has agreed to take all necessary actions to effect such appointment and to amend its bylaws to provide for co-chairmen of the Board, with each co-chairman having the same rights and responsibilities.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Serina Therapeutics, Inc. amended a notes offering with holders of its outstanding Senior Unsecured Convertible Promissory Note.
- Action
- amendment
- Agreement
- notes offering
- Counterparty
- holders of its outstanding Senior Unsecured Convertible Promissory Note
Exact text from the filing
As a condition to the initial closing, the Company and the holders of its outstanding Senior Unsecured Convertible Promissory Note, dated September 9, 2025, entered into an amendment of such note, effective upon the initial closing, removing any further obligations to borrow or loan funds under the Note.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Serina Therapeutics, Inc. entered into Securities Purchase Agreement with Greg Bailey, as lead investor, and certain other investors valued at $15.0 million (effective 2026-03-17).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Greg Bailey, as lead investor, and certain other investors
- Value
- $15.0 million
- Effective
- 2026-03-17
Exact text from the filing
On March 17, 2026, Serina Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with Greg Bailey, as lead investor, and certain other investors (collectively, the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Private Placement ”), shares of its common stock, par value $0.0001 per share (the “ Common Stock ”), pre-funded warrants to purchase shares of Common Stock (the “ Pre-Funded Warrants ”) redeemable warrants to purchase shares of Common Stock (the “ Redeemable Warrants ” and, together with the Common Stock and the Pre-Funded Warrants, the “ Securities ”).
View on SEC.gov